A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy in adults with advanced biliary tract cancer

Prior treatment

• Any prior systemic therapy received for unresectable locally advanced or metastatic BTC.
• Any prior exposure to any therapy targeting immune-regulatory receptors or mechanisms.
• Any concurrent chemotherapy, radiotherapy, immunotherapy, investigational, biologic, or hormonal therapy for cancer treatment other than those under investigation in this study.
• Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.

Other illness

• Active or ongoing interstitial lung disease/pneumonitis (of any grade), serious chronic gastrointestinal conditions associated with diarrhea, or active non-infectious skin disease (including any grade rash, urticaria, dermatitis, ulceration, or psoriasis) requiring systemic treatment.

Other

• Ampullary carcinoma.

• Histologically confirmed adenocarcinoma of the biliary tract, including intra-hepatic or extra-hepatic cholangiocarcinoma (CCA) and gallbladder carcinoma (GBC).
• Unresectable locally advanced or metastatic BTC, previously untreated in the advanced disease setting.
• Known PD-L1 status assessed at a central laboratory using an acceptable tumor sample.
• Measurable disease by RECIST 1.1 criteria using CT or MRI and is suitable for accurate repeated measurements.
• ECOG Performance Status of 0 or 1 with no deterioration (ie, ECOG PS > 1) over the previous 2 weeks prior to baseline at screening and prior to randomization.
• Adequate bone marrow and organ function.